Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGJL16)

Drug Name

LE-300 Drug Info

Synonyms

L 8401; LE 300; 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Preclinical	[1]

Cross-matching ID

PubChem CID: 4350931
ChEBI ID: CHEBI:92030
CAS Number: CAS 274694-98-3
TTD Drug ID: DMGJL16

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Dopamine D5 receptor (D5R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[4]
ZD-3638	DM6M9GC	Schizophrenia	6A20	Terminated	[1]
GMC-283	DMT1RH6	Schizophrenia	6A20	Terminated	[1]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[5]
ISOCLOZAPINE	DM52CPU	Discovery agent	N.A.	Investigative	[6]
FLUMEZAPINE	DMW0HOG	Discovery agent	N.A.	Investigative	[7]
ISOLOXAPINE	DMH1BN4	Discovery agent	N.A.	Investigative	[8]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine	DMOL2Y0	Discovery agent	N.A.	Investigative	[6]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine	DMD2NXL	Discovery agent	N.A.	Investigative	[4]
STEPHOLIDINE	DMGMXQC	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By D(1B) dopamine receptor (DRD5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[11]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[12]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[13]
PMID28870136-Compound-48	DMPIM9L	N. A.	N. A.	Patented	[14]
------------------------------------------------------------------------------------

Drug(s) Affected By D(1A) dopamine receptor (DRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[15]
Haloperidol	DM96SE0	Delirium		Approved	[16]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[17]
Pergolide mesylate	DM5GKOV	N. A.	N. A.	Approved	[18]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[16]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[19]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[11]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[20]
Methamphetamine	DMPM4SK	Anxiety		Approved	[21]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[22]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By 5-hydroxytryptamine receptor 2C (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[23]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[23]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[23]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[26]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[27]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[28]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[29]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[30]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By D(3) dopamine receptor (DRD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Haloperidol	DM96SE0	Delirium		Approved	[31]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[32]
Risperidone	DMN6DXL	Bipolar I disorder		Approved	[33]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[34]
Methamphetamine	DMPM4SK	Anxiety		Approved	[35]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[36]
Droperidol	DM0DXA8	Nausea	MD90	Approved	[15]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[15]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[15]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D5 receptor (D5R)	TTS2PH3	DRD5_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5-hydroxytryptamine receptor 2C (HTR2C)	OT6H8DE0	5HT2C_HUMAN	Protein Interaction/Cellular Processes	[2]
D(1A) dopamine receptor (DRD1)	OTLZPBT7	DRD1_HUMAN	Protein Interaction/Cellular Processes	[3]
D(1B) dopamine receptor (DRD5)	OTYVGPOP	DRD5_HUMAN	Protein Interaction/Cellular Processes	[3]
D(3) dopamine receptor (DRD3)	OT0OFFKB	DRD3_HUMAN	Protein Interaction/Cellular Processes	[2]

------------------------------------------------------------------------------------

References

1	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
2	Dopamine/serotonin receptor ligands. Part VIII: the dopamine receptor antagonist LE300 - modelled and X-ray structure plus further pharmacological characterization, including serotonin receptor binding, biogenic amine transporter testing and in vivo testings. Eur J Med Chem. 2004 Jun;39(6):481-9. doi: 10.1016/j.ejmech.2004.02.001.
3	Chiral indolo[3,2-f][3]benzazecine-type dopamine receptor antagonists: synthesis and activity of racemic and enantiopure derivatives. J Med Chem. 2011 Oct 27;54(20):7422-6. doi: 10.1021/jm200676f. Epub 2011 Sep 29.
4	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
5	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
6	Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
7	Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
8	Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
9	Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
10	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
11	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
12	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
13	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
14	Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
15	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
16	Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
17	Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992 Jul;49(7):538-44. doi: 10.1001/archpsyc.1992.01820070032005.
18	Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation. 2005 Sep 6;112(10):1494-9. doi: 10.1161/CIRCULATIONAHA.105.556704. Epub 2005 Aug 29.
19	Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain. Clin Exp Pharmacol Physiol. 2010 May;37(5-6):613-8. doi: 10.1111/j.1440-1681.2010.05364.x. Epub 2010 Feb 4.
20	Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
21	Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry. 2000 Nov;5(6):664-72. doi: 10.1038/sj.mp.4000760.
22	Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol. 2007 Sep;21(7):718-27. doi: 10.1177/0269881106072341. Epub 2006 Nov 8.
23	Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
24	Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
25	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
26	Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol. 1993;16 Suppl 3:S19-31.
27	Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
28	Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
29	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
30	Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
31	The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3779-82. doi: 10.1016/j.bmcl.2003.07.015.
32	Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 2010 Jun;10(3):200-18. doi: 10.1038/tpj.2009.65. Epub 2009 Dec 22.
33	A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J. 2009 Dec;9(6):404-10. doi: 10.1038/tpj.2009.26. Epub 2009 Jun 9.
34	Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
35	Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci. 2009 Nov 25;29(47):14734-40. doi: 10.1523/JNEUROSCI.3765-09.2009.
36	Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry. 2009 Oct;166(10):1170-7. doi: 10.1176/appi.ajp.2009.08121801. Epub 2009 Sep 1.